Viracta Therapeutics Announces the Appointment of Flavia Borellini, Ph D , and Jane F Barlow, M D , MPH, MBA, to its Board of Directors
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Viracta Therapeutics Announces the Appointment of Flavia Borellini, Ph D , and Jane F Barlow, M D , MPH, MBA, to its Board of Directors
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office
May 03, 2021 07:30 ET | Source: ContraFect Corporation ContraFect Corporation Yonkers, New York, UNITED STATES
YONKERS, N.Y., May 03, 2021 (GLOBE NEWSWIRE) ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 10,988,520 (the ‘520 patent), on April 27, 2021 for CF-370, the company’s second potential therapeutic product candidate. The ‘520 patent, which is owned by ContraFect, expires in March of 2039, and is the latest U.S. patent to issue from the company’s DLA patent portfolio